A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

Jan Sørensen CAST – Centre for Applied Health Services Research and Technology Assessment, University of Southern Denmark, J. B. Winsløws Vej 9B, DK-5000, Odense C, DenmarkCorrespondence[email protected]

, M.Sc.(health econ.),

Kurt B. Stage Department of Psychiatry, Odense University Hospital, DK-5000, Odense C, Denmark

, Ph.D. , M.D.,

Niels Damsbo Institute of Public Health – General Practice, University of Southern Denmark, J. B. Winsløws Vej 9A, DK-5000, Odense C, Denmark

, M.D.,

Agathe Le Lay H. Lundbeck A/S, Economics and Pricing Division, International Health Economics and Epidemiology Department, Paris, France, (at the time of the analyses)

, M.Sc. &

Michiel E. Hemels H. Lundbeck A/S, Economics and Pricing Division, International Health Economics and Epidemiology Department, Paris, France, (at the time of the analyses)

, Drs. , MSc

A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date